Gainers

• Beyond Air (NASDAQ:XAIR) shares increased by 183.1% to $2.48 during Tuesday's regular session. The company's market cap stands at $7.0 million.
• AlphaTON Capital (NASDAQ:ATON) stock rose 106.36% to $1.88. The company's market cap stands at $7.4 million.
• XTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 65.41% to $1.13. The market value of their outstanding shares is at $6.0 million.
• Decoy Therapeutics (NASDAQ:DCOY) stock moved upwards by 44.78% to $1.18. The market value of their outstanding shares is at $4.7 million.
• BriaCell Therapeutics (NASDAQ:BCTX) shares rose 30.49% to $9.97. The company's market cap stands at $14.3 million.
• Fortress Biotech (NASDAQ:FBIOP) shares increased by 25.08% to $12.74. The company's market cap stands at $34.9 million.

Losers

• Travere Therapeutics (NASDAQ:TVTX) shares declined by 32.3% to $23.1 during Tuesday's regular session. The market value of their outstanding shares is at $3.0 billion.
• Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) shares fell 24.97% to $0.15.
• Atara Biotherapeutics (NASDAQ:ATRA) stock decreased by 19.73% to $4.72. The market value of their outstanding shares is at $42.3 million.
• Inspire Veterinary (NASDAQ:IVP) shares decreased by 19.32% to $0.03. The market value of their outstanding shares is at $1.5 million.
• China SXT Pharmaceuticals (NASDAQ:SXTC) shares decreased by 17.64% to $0.12. The company's market cap stands at $16.5 million.
• Regencell Bioscience (NASDAQ:RGC) stock decreased by 16.08% to $37.02. The company's market cap stands at $21.8 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.